keyword
MENU ▼
Read by QxMD icon Read
search

pemphigus rituximab

keyword
https://www.readbyqxmd.com/read/29469734/clinical-resolution-of-pemphigus-vulgaris-on-rituximab
#1
Elizabeth Cusick, David Silverstein
Although significant progress has been made for the treatment of pemphigus vulgaris (PV) with rituximab (RTX), a consensus remains to be determined for standard treatment protocol, regarding optimal dosing, infusion regimen, and use of concomitant immunotherapy to achieve safe, effective, and rapid clinical response. We describe a patient with pemphigus vulgaris treated with high dose rituximab with the rheumatoid arthritis protocol along with intravenous immunoglobulin therapy. This case provides evidence towards the growing body of research needed to modify and improve treatment for pemphigus using rituximab...
September 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29453873/association-between-pemphigus-and-neurologic-diseases
#2
Khalaf Kridin, Shira Zelber-Sagi, Doron Comaneshter, Arnon D Cohen
Importance: The association between pemphigus and neurologic diseases was not evaluated systematically in the past. In a recent uncontrolled cross-sectional study, Parkinson disease was found to be significantly associated with pemphigus; in the same study, epilepsy had a nonsignificant association with pemphigus. Several case reports have suggested that pemphigus coexists with multiple sclerosis and dementia. Objective: To estimate the association between pemphigus and 4 neurologic conditions (dementia, epilepsy, Parkinson disease, and multiple sclerosis), using one of the largest cohorts of patients with pemphigus...
February 16, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29453868/coexistent-solid-malignancies-in-pemphigus-a-population-based-study
#3
Khalaf Kridin, Shira Zelber-Sagi, Doron Comaneshter, Arnon D Cohen
Importance: The association of pemphigus vulgaris and pemphigus foliaceus with comorbid malignancies is yet to be firmly established. Objective: To estimate the association between pemphigus and a wide range of nonhematologic malignancies using one of the largest cohorts of patients with pemphigus to date. Design, Setting, and Participants: For this cross-sectional study, we used the computerized database of Clalit Health Services, the largest public health care provider organization in Israel insuring 4...
February 16, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29447659/paraneoplastic-pemphigus-in-a-34-year-old
#4
Laura E Melnick, Jenna M Beasley, Randi Kim, Nooshin Brinster, Kristen Lo Sicco
Paraneoplastic Pemphigus (PNP) is a rare and often fatal autoimmune mucocutaneous blistering disease associated with an underlying malignancy. It is thought to be caused by antibodies to tumor antigenscross-reacting with epithelial antigens, specifically desmosomal and hemidesmosomal antigens. There are at least five clinical morphologic variants of PNP, with the earliest and most consistent finding beingsevere stomatitis. Diagnosis of PNP requires direct immunofluorescence of perilesional skin and indirect immunofluorescence...
December 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29447653/rituximab-and-intravenous-immunoglobulin-as-alternatives-to-long-term-systemic-corticosteroids-in-the-treatment-of-pemphigus-a-single-center-case-series-of-63-patients
#5
Ashley E Brown, Kiran Motaparthi, Sylvia Hsu
Rituximab and intravenous immunoglobulin [IVIg] have recently emerged as effective treatments for pemphigus refractory to corticosteroids [CS]. This case series sought to compare the clinical, serologic,and adverse effects of CS, IVIg, and rituximab in patients with pemphigus. A retrospective review of 63 patients with pemphigus vulgaris (PV), pemphigus foliaceus (PF), or paraneoplastic pemphigus (PNP)was performed. Clinical remission (CR), serologic remission (SR), and adverse effects were evaluated. Three study groups were compared: patients treated with systemic CS, refractory patients treated withIVIg, and refractory patients treated with rituximab...
January 19, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29408700/a-prospective-study-comparing-patients-with-early-and-late-relapsing-pemphigus-treated-with-rituximab
#6
Marwah Adly Saleh
BACKGROUND: Rituximab (RTX) is an effective therapy for patients with pemphigus. However it does not prevent relapse. OBJECTIVES: To compare early relapsing patients (before 12 months) and late relapsing patients (after 24 months) following RTX therapy. METHODS: In this prospective study, 19 patients were enrolled (14 pemphigus vulgaris and 5 pemphigus foliaceus). The baseline disease score, autoantibodies, and percentage of CD20+ cells of pemphigus patients were measured...
January 30, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29313220/pemphigus-a-comprehensive-review-on-pathogenesis-clinical-presentation-and-novel-therapeutic-approaches
#7
REVIEW
Robert Pollmann, Thomas Schmidt, Rüdiger Eming, Michael Hertl
Pemphigus is a group of rare, potentially devastating autoimmune diseases of the skin and mucous membranes with high morbidity and potentially lethal outcome. The major clinical variant, pemphigus vulgaris (PV) is caused by a loss of intercellular adhesion of epidermal keratinocytes which is induced by IgG autoantibodies against components of desmosomes. Specifically, IgG against the desmosomal adhesion proteins, desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1), preferentially target their ectodomains which are presumably critical for the transinteraction and signalling function of these adhesion molecules...
January 8, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29299590/rituximab-as-single-long-term-maintenance-therapy-in-patients-with-difficult-to-treat-pemphigus
#8
Julia Sanchez, Saskia Ingen-Housz-Oro, Olivier Chosidow, Frank Antonicelli, Philippe Bernard
No abstract text is available yet for this article.
January 3, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29192985/rituximab-and-short-course-prednisone-as-the-new-gold-standard-for-new-onset-pemphigus-vulgaris-and-pemphigus-foliaceus
#9
EDITORIAL
D F Murrell, E Sprecher
No abstract text is available yet for this article.
November 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29146127/rituximab-as-first-line-adjuvant-in-pemphigus-retrospective-analysis-of-the-long-term-outcomes-in-a-single-center
#10
Keshavamurthy Vinay, Simone Cazzaniga, Kyle T Amber, Laurence Feldmeyer, Luigi Naldi, Luca Borradori
No abstract text is available yet for this article.
November 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29132070/sixteen-year-history-of-rituximab-therapy-for-1085-pemphigus-vulgaris-patients-a-systematic-review
#11
REVIEW
Soheil Tavakolpour, HamidReza Mahmoudi, Kamran Balighi, Robabeh Abedini, Maryam Daneshpazhooh
Pemphigus vulgaris (PV) is a rare autoimmune disease due to the production of pathogenic autoantibodies directed against desmoglein 1 and 3, usually affecting both skin and mucous membranes. Recently, rituximab, a chimeric IgG1 monoclonal antibody which targets the CD20 molecules have been regarded as a promising treatment for PV. In this study, a systematic review was conducted to conclude on how and which PV patients could benefit from rituximab infusion. Search in PubMed results in 114 relevant studies, which met the criteria...
November 10, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29131038/bullous-diseases
#12
Caroline Corbaux, Pascal Joly
Autoimmune bullous diseases are a heterogeneous group of blistering diseases affecting the skin and/or mucous membrane. Systemic corticosteroids, which are often associated with immunosuppressants, are the main treatment option for these diseases. The 2 main biologics used in the treatment of autoimmune bullous diseases are rituximab, especially in pemphigus and mucous membrane pemphigoid, and omalizumab in bullous pemphigoid. Rituximab is a promising therapeutic option in pemphigus and mucous membrane pemphigoid...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29107213/current-and-future-treatment-options-for-pemphigus-is-it-time-to-move-towards-more-effective-treatments
#13
REVIEW
Soheil Tavakolpour
Systemic administration of corticosteroid (CS) remains the standard gold treatment for pemphigus. However, because of several long-term adverse effects, steroid-sparing agents are usually prescribed in combination with CSs. Despite the high number of available studies, the choice of best drugs to treat pemphigus remains controversial. Therapeutic approaches for pemphigus can be divided into traditional treatment and emerging ones. Personalized medicine, which aims to increase the efficacy as well as reduce adverse effects of treatments, could be considered as the future option...
December 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29064314/rituximab-in-pemphigus
#14
Vivien Hebert, Pascal Joly
Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies. Its therapeutic role in pemphigus has been progressively growing with increasing evidence of successful outcomes. Rituximab was initially off-labeled used as an alternative in patients with recalcitrant or relapsing pemphigus and in patients with contraindications to systemic corticosteroids...
October 24, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28927663/developing-biomarkers-for-predicting-clinical-relapse-in-pemphigus-patients-treated-with-rituximab
#15
Lauren N Albers, Yuan Liu, Na Bo, Robert A Swerlick, Ron J Feldman
BACKGROUND: Rituximab is an effective therapy for pemphigus, although relapses are common. OBJECTIVE: To identify biomarkers to predict relapse of pemphigus following rituximab treatment. METHODS: In this retrospective cohort study, 62 patients with pemphigus treated with 99 rituximab cycles provided longitudinal clinical scoring and biomarker data, including levels of CD19 + B cells, CD4 + T cells, and desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) autoantibodies...
December 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28802491/rf-rituximab-revolutionizing-the-treatment-of-pemphigus
#16
D Morgado-Carrasco, P Giavedoni, X Fustà-Novell, P Iranzo
No abstract text is available yet for this article.
August 9, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28794567/autoimmune-bullous-disease-in-childhood
#17
Andac Salman, Burak Tekin, Deniz Yucelten
BACKGROUND: Autoimmune bullous disorders (AIBDs) are a heterogeneous group of diseases which are rarely seen in children. Studies concerning the immunobullous diseases in pediatric patients are scarce. AIMS AND OBJECTIVES: In this study, we aimed to investigate the clinical features and treatment outcomes of AIBDs in children. MATERIALS AND METHODS: The electronic records of the patients in our AIBDs outpatient clinic were retrospectively reviewed...
July 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28791608/achievement-of-the-longest-survival-of-paraneoplastic-pemphigus-with-bronchiolitis-obliterans-associated-with-follicular-lymphoma-using-r-chop-chemotherapy
#18
Shin Lee, Takahiro Yamauchi, Norito Ishii, Takashi Hashimoto, Keiichi Kinoshita, Shin Imamura, Kenichi Kamiya
Paraneoplastic pemphigus (PNP) is a rare, fatal, paraneoplastic autoimmune mucocutaneous blistering disease, commonly associated with lymphoproliferative disorders, including malignant lymphomas. Lymphoproliferative disorders associated with PNP are sometimes associated with a serious lung complication, bronchiolitis obliterans (BO). Due to its rarity, guidelines for the management of PNP have not been established. Furthermore, most patients die within 1 year. Here we report the successful treatment of lymphoma-associated PNP and BO using R-CHOP chemotherapy...
December 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28758262/paraneoplastic-pemphigus-seen-in-4-patients-with-hematologic-malignancies-formerly-treated-with-rituximab
#19
C Baykal, S Kılıç, R Küçükoğlu
Paraneoplastic pemphigus (PNP) is a peculiar variant of pemphigus with pathognomonic clinical, histological, and immunological features. It is typically associated with hematologic malignancies (84%), such as non-Hodgkin lymphomas (NHL) (most common), chronic lymphocytic leukemia (CLL), Castleman disease, thymoma, Waldenström's macroglobulinemia, Hodgkin lymphoma, and monoclonal gammopathy, as well as non-hematological neoplasms, such as epithelial carcinomas, mesenchymal sarcomas, and malignant melanoma. This article is protected by copyright...
July 31, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28724275/a-case-report-of-paraneoplastic-pemphigus-associated-with-retroperitoneal-inflammatory-myofibroblastic-tumor
#20
Kamran Balighi, Arghavan Azizpour, Ali Sadeghinia, Vahide Saeidi
Paraneoplastic pemphigus (PNP) is an autoimmune bullous disease associated with underlying neoplasms, both malignant and benign. The most constant clinical presentation of PNP is the presence of intractable stomatitis. Herein we present a 25-year-old male with a 3-month history of refractory stomatitis especially involving the lips and widespread vesiculobullous eruption on his trunk and extremities. The diagnosis of PNP was confirmed based on histological and serological results. Investigation for the underlying neoplasm revealed a retroperitoneal tumorous mass which was biopsied and diagnosed as the inflammatory myofibroblastic tumor (IMT)...
May 2017: Acta Medica Iranica
keyword
keyword
82673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"